Bausch + Lomb BLCO
CanadaHealthcare · Medical Instruments & SuppliesUSD
19.39 USD (+11.8%)
14 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Bausch + Lomb Corporation is a global eye health company that designs, manufactures, and markets contact lenses, eye care solutions, ophthalmic pharmaceuticals, and surgical equipment for cataract and refractive surgery procedures.
Key points
from its scores- ✓Favourable backdrop8.1
- ✓Good share-price trend7.4
- ✕Little or no dividend1.5
- ✕Fragile balance sheet3.1
- ✕Little competitive advantage4.0
AI analysis
bottom line, main risk, context and newsThe company has a quality business with high margins, but high leverage and negative return on equity warrant caution until sustained debt reduction is demonstrated.
Bausch + Lomb shows revenue growth of 9.10% and a gross margin of 61.44%, but its financial health is fragile with a Net Debt/EBITDA of 5.82 and a negative ROE (-2.52%), which limits its appeal despite a reasonable valuation (forward P/E 15.58).
The main risk is high leverage (Net Debt/EBITDA of 5.82), which in a rising interest rate environment could increase financial costs and limit the capacity for investment and growth.
Context and risks
Bausch + Lomb operates in the medical devices and ophthalmology sector, an area with ongoing regulatory oversight (FDA, Health Canada) that can affect product approvals and labeling. Governance risk in Canada is moderate, adding a slight jurisdictional risk premium.
Is Bausch + Lomb stock cheap or expensive?
at the analysis dateOn EV / EBITDA, it trades in line with the Healthcare median (within 15%).
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| EV / EBITDA | 13.5 | 14.5 | −7% |
| Price / book | 1.0 | 4.1 | −77% |
| Price / sales | 1.2 | 3.4 | −66% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 5.0 out of 10 (median for Healthcare: 4.7).
Average analyst target: 19.39 USD, +11.8% versus the price.
Classic formulas with standard assumptions (5.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- Forward P/E
- 15.6
- EV / EBITDA
- 13.5
- Price / book
- 1.0
- Price / sales
- 1.2
- PEG
- 0.89
- Market cap
- 6.2B USD
- Enterprise value
- 11.0B USD
Profitability
- ROE
- −2.5%
- ROA
- 1.8%
- ROIC (approx.)
- 3.6%
- Gross margin
- 61.4%
- Operating margin
- 7.7%
- Net margin
- −3.2%
- Free cash flow
- 323.0M USD
- FCF yield
- 5.2%
- Cash conversion
- 40%
Solvency
- Total debt
- 5.1B USD
- Net debt
- 4.7B USD
- Cash
- 367.0M USD
- EBITDA
- 816.0M USD
- Net debt / EBITDA
- 5.82
- Debt / equity
- 79.38
- Current ratio
- 1.55
- Quick ratio
- 0.81
Growth
- Revenue growth
- +9.1%
- EPS (TTM)
- −0.49 USD
- EPS (forward)
- 1.11 USD
Dividend
- Dividend yield
- 0.0%
- Payout
- 0.0%
Risk and market
- Beta
- 0.56
- Analyst consensus
- Buy (14)
- Target price
- 19.39 USD
- 52-week range
- 13.77 – 18.91
Recent news
All BLCO news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Bausch + Lomb
Is Bausch + Lomb stock cheap or expensive?
On EV / EBITDA, it trades in line with the Healthcare median (within 15%). Valuation score: 5.0 out of 10 (median for Healthcare: 4.7). Average analyst target: 19.39 USD, +11.8% versus the price. This is not investment advice.
What score does Bausch + Lomb get on MeridIAn Screener?
It scores 5.1 out of 10, rank 1,632 of 2,130 (better than 21% of the companies analysed). Its strongest category is Risk & Context (8.1) and its weakest, Dividend (1.5). Analysis of 08/10/2026.
How much is Bausch + Lomb worth on the stock market?
Its market capitalisation is 6.2B USD and its enterprise value, debt included, is 11.0B USD.
How much debt does Bausch + Lomb have?
Its net debt (debt minus cash) is 4.7B USD. That is 5.82 times its EBITDA; the Healthcare median is 1.53.
Does Bausch + Lomb pay a dividend?
It pays no dividend, or almost none.
How has Bausch + Lomb stock performed over the last year?
It has risen 21.1% over the last year, excluding dividends. Over the last 52 weeks it has traded between 13.77 and 18.91 USD. Past performance does not guarantee future results.
What do analysts think of Bausch + Lomb?
14 analysts cover it; their average recommendation is “Buy” and their average target is 19.39 USD (+11.8% versus the price). It is an estimate, not market data.